KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Cited by (1,002)

Items 801–900 of 1,002

1. Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
   Y Li, Zhicheng Jin, Sharif U. Ahmed, Jagotamoy Das, Reiner Bleher, Dingran Chang, Xiaozhou Yu, Connor D. Flynn, Jiajing Zhou, Xiaobing Hu et al. · 2026 · Nature Communications
2. Sotorasib – an inhibitor of KRAS p.G12c mutation in advanced non-small cell carcinoma
   Amit Kumar Agrawal, Ramya Pragya, Amit Choudhary, Anuj Kumar Gupta, Kuraparthy Sambasivaiah, Bal Krishna Mishra, Satvik Khaddar, Akhil Kapoor · 2021 · Cancer Research Statistics and Treatment
3. Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy
   Guowei Yin, Guohua Lv, Jerry Zhang, Hongmei Jiang, Tianqi Lai, Yushan Yang, Yong Ren, Jing Wang, Chenju Yi, Hao Chen et al. · 2022 · Pharmacology & Therapeutics
4. Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
   Paola Ulivi, Milena Urbini, Elisabetta Petracci, Matteo Canale, Alessandra Dubini, Daniela Bartolini, Daniele Calistri, Paola Cravero, Eugenio Fonzi, Giovanni Martinelli et al. · 2022 · Cancers
5. Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
   Simona Ruxandra Volovăț, Iolanda Georgiana Augustin, Daniela Zob, Diana Boboc, Florin Amurariti, Constantin D. Volovat, Cipriana Ştefănescu, Cati Raluca Stolniceanu, Manuela Ciocoiu, Eduard Alexandru Dumitras et al. · 2022 · Cancers
6. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients
   Xianyu Liu, Deze Zhao, Yunhan Shan, Weifang Cui, Qun Xie, Junjie Jiang, Wei Peng, Chunfang Zhang, Chaojun Duan · 2022 · Scientific Reports
7. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition
   Pedro Barrios‐Bernal, José Lucio-Lozada, Maritza Ramos-Ramírez, Norma Hernández‐Pedro, Oscar G. Arrieta · 2023 · International Journal of Molecular Sciences
8. KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
   Shenyi Lian, Lu-Xin Tan, Xin-Zhi Liu, Lujing Yang, Ning-Ning Li, Qing Feng, Ping Wang, Yue Wang, Dongbo Qiao, Lixin Zhou et al. · 2023 · Medicine
9. New insights into RAS in head and neck cancer
   Sankar Jagadeeshan, Ofra Novoplansky, Oded M. Cohen, Ina Kurth, Jochen Heß, Ari Joseph Rosenberg, Jennifer Rubin Grandis, Moshe Elkabets · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
10. Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment
    Robert Kleszcz · 2023 · Cancers
11. Assessment of KRASG12C inhibitors for colorectal cancer
    Gary Anthony Piazza, Preethi Chandrasekaran, Yulia Y. Maxuitenko, Karim I. Budhwani · 2024 · Frontiers in Oncology
12. Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives
    Ari Hashimoto, Shigeru Hashimoto · 2024 · Cancers
13. Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies
    Apurva Kumari Pandey, Peter J. Rohweder, Lieza M. Chan, Chayanid Ongpipattanakul, Dong hee Chung, Bryce Paolella, Fiona M. Quimby, Ngọc Bích Nguỹên, Kliment A. Verba, Michael J. Evans et al. · 2024 · Cancer Research
14. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
    Alfredo Tartarone, Vittoria Lapadula, Concetta Di Micco, Gemma Rossi, Carlotta Ottanelli, Andrea Marini, Roberta Giorgione, Katia Ferrari, Martina Catalano, Luca Voltolini et al. · 2021 · Frontiers in Oncology
15. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
    Seyed Saeed Pairawan, Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Q. Rizvi, Vijaykumar R. Holla, Jing Wang et al. · 2022 · Scientific Reports
16. KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations
    Pim B. Olthof, Stefan Buettner, Nikolaos Andreatos, Jane Wang, Inger Marie Løes, Doris Wagner, Kazunari Sasaki, Andrea Macher-Beer, Carsten Kamphues, Ioannis Pozios et al. · 2022 · British journal of surgery
17. Targeting Molecular Alterations in Non-Small-Cell Lung Cancer: What’s Next?
    Rafael López Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita · 2022 · Personalized Medicine
18. State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
    Yung‐Hung Luo, Kung‐Hao Liang, Hsu-Ching Huang, Chia‐I Shen, Chi‐Lu Chiang, Mong‐Lien Wang, Shih‐Hwa Chiou, Yuh‐Min Chen · 2022 · International Journal of Molecular Sciences
19. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
    Liyuan Gao, Weizhang Shen · 2022 · Frontiers in Genetics
20. Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy
    Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher, Sara Monteverdi, Salvatore Girlando, Mattia Barbareschi, Orazio Caffo · 2022 · Targeted Oncology
21. Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers
    Katarzyna M. Tyc, Aslamuzzaman Kazi, Alok Ranjan, Rui Wang, Saı̈d M. Sebti · 2023 · iScience
22. Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing
    Yonggang He, Wen Jing Huang, Yichen Tang, Yuming Li, Xuehui Peng, Jing Li, Jing Yun Wu, Nan You, Ling Li, Chuang Liu et al. · 2023 · Frontiers in Oncology
23. Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors
    Kathryn Cecilia Arbour, Piro Lito · 2022 · Journal of Clinical Oncology
24. Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
    Lee, Chaeyoung, Yi, Jawoon, Park, Jihwan, Ahn, Byungyong, Won, Young-Wook, Jeon, JiHeung, Lee, Byung Ju, Cho, Wha Ja, Park, Jeong Woo · 2024 · Cell Death & Disease
25. An Emerging Role of KRAS in Biogenesis, Cargo Sorting and Uptake of Cancer-Derived Extracellular Vesicles
    Zhijack Fong, Wai-Leng Lee · 2022 · Future Medicinal Chemistry
26. Emerging Tumor-Agnostic Molecular Targets
    Dedipya Bhamidipati, Alison M. Schram · 2024 · Molecular Cancer Therapeutics
27. Histology Agnostic Drug Development: An Updated Review
    Kevin Nguyen, Karina B Fama, Guadalupe Mercado, Yin Mon Myat, Kyaw Zin Thein · 2024 · Cancers
28. KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
    Rebecca Gelfer, Aistė Gulla, Hannah L. Kalvin, Yi Song, James J. Harding, Ghassan K. Abou‐Alfa, Eileen Mary O'Reilly, Wungki Park, Rohit Chandwani, Alice Chia-Chi Wei et al. · 2024 · JCO Precision Oncology
29. MAI-TargetFisher: A proteome-wide drug target prediction method synergetically enhanced by artificial intelligence and physical modeling
    Shiwei Li, Pengxuan Ren, Lin Wang, Qilei Han, Fenglei Li, Honglin Li, Fang Bai · 2025 · Acta Pharmacologica Sinica
30. COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale
    Hanfeng Lin, Bin Yang, Lang Ding, Yen‐Yu Yang, Matthew Valle Holt, Sung Yun Jung, Bing Zhang, Meng Carla Wang, Jin Wang · 2025 · Nature Communications
31. Vascular malformations: from genetics to therapeutics
    G Morin, Ilaria Galasso, Guillaume Canaud · 2025 · EMBO Molecular Medicine
32. AKR1B10 reprograms neutrophils by histone lactylation to foster immune evasion in KRASG12C mutation colorectal cancer liver metastasis
    Weiwei Li, Wenkang Yuan, Zihao Du, Xiangyu Ivy Wang, Daoyue Wang, Songlin Xing, Tingting Shen, Canliang Lu, Jiale Chen, Anhai Yu et al. · 2026 · Journal of Experimental & Clinical Cancer Research
33. Late phase 1 studies: concepts and outcomes
    José Carlos Benítez, Arthur Géraud, Matthieu Texier, Christophe Massard, Angélo Paci, Jean‐Charles Soria, Benjamin Besse · 2021 · The Lancet Oncology
34. HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
    Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, Charlotte Fenat, Jaafar Bennouna, Christophe Blanquart, Marc Guillaume Denis, Elvire Pons Tostivint · 2022 · Current Oncology
35. AZD4625 is a Potent and Selective Inhibitor of KRASG12C
    Atanu Chakraborty, Lyndsey L. Hanson, David M. Robinson, Hilary J. Lewis, Sue Bickerton, Michael Davies, Radosław Polański, Rebecca Whiteley, Alex Koers, James M. Atkinson et al. · 2022 · Molecular Cancer Therapeutics
36. Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure
    Alexandra Maria Psaras, Rhianna K. Carty, Jared T. Gillen Miller, L. Nathan Tumey, Tracy Ann Brooks · 2022 · Genes
37. Landscape of the clinical development of China innovative anti-lung cancer drugs
    Yuankai Shi · 2022 · Cancer Pathogenesis and Therapy
38. Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients
    Soukaina Benmokhtar, Abdelilah Laraqui, Fatima El Boukhrissi, Farida Hilali, Tahar Bajjou, Meryem Jafari, Sara El Zaitouni, Walid Baba, Bouchra El Mchichi, Hicham Elannaz et al. · 2022 · Asian Pacific Journal of Cancer Prevention
39. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
    Hiroyuki Matsubara, Hiroyuki Miyoshi, Fumihiko Kakizaki, Tomonori Morimoto, Kenji Kawada, Takehito Yamamoto, Kazutaka Obama, Yoshiharu Sakai, Makoto Mark Taketo · 2023 · Molecular Cancer Therapeutics
40. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
    Xiao‐Dong Jiao, Bao‐Dong Qin, Zhan Wang, Ke Liu, Ying Wu, Yan Ling, Wenxing Qin, Miaomiao Wang, Lingyan Yuan, Savio George Barreto et al. · 2023 · Frontiers in Oncology
41. KRAS mutations upregulate Runx1 to promote occurrence of head and neck squamous cell carcinoma
    Miao Deng, Jiaxin Guo, Zihang Ling, Chi Zhang, Lihong He, Zhaona Fan, Bin Cheng, Juan Xia · 2023 · Molecular Carcinogenesis
42. Cuproptosis‐related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients
    Yanling Wang, Weiyu Ge, Shengbai Xue, Jiujie Cui, Xiaofei Zhang, Tiebo Mao, Haiyan Xu, Shumin Li, Jingyu Ma, Ming Yue et al. · 2023 · IET Systems Biology
43. Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
    Deepak Bhamidipati, Vivek Subbiah · 2023 · ESMO Open
44. A Combination of Conformation-Specific RAF Inhibitors Overcome Drug Resistance Brought about by RAF Overexpression
    Hiroaki Imoto, Nora Rauch, Ashish Neve, Fahimeh Khorsand, Martina Kreileder, Leonidas G. Alexopoulos, Jens Rauch, Mariko Okada, Boris Ν. Kholodenko, Oleksii S. Rukhlenko · 2023 · Biomolecules
45. Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis
    Wei Ping Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke Xu · 2023 · Expert Review of Anticancer Therapy
46. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
    Jimi Kim · 2023 · International Journal of Molecular Sciences
47. The Importance of KRAS Quantification for a Clinicopathological Characterization in Colorectal Cancer Patients
    Alexandru Adrian Bratei, Raluca‐Ioana Stefan‐van Staden · 2023 · Medinformatics
48. Multisequence MRI-based radiomics signature as potential biomarkers for differentiating KRAS mutations in non-small cell lung cancer with brain metastases
    Xinna Lv, Ye Li, Bing Wang, Yichuan Wang, Zexuan Xu, Dailun Hou · 2024 · European Journal of Radiology Open
49. Protein tyrosine phosphatases: emerging role in cancer therapy resistance
    Min Zhao, Wen Shuai, Zehao Su, Ping Xu, Aoxue Wang, Qiu Sun, Guan Wang · 2024 · 癌症：英文版
50. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers
    Tarık Demir, Carolyn Moloney, Devalingam Mahalingam · 2024 · Critical Reviews in Oncology/Hematology
51. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
    Chiara Musiu, Francesca Lupo, Antonio Agostini, Gabriella Lionetto, Michele Bevere, Salvatore Paiella, Carmine Carbone, Vincenzo Corbo, Stefano Ugel, Francesco De Sanctis · 2024 · Frontiers in Immunology
52. Feasibility and clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling in pancreatic cancer: A systematic review and meta-analysis
    Sung Woo Ko, Ik Hyun Jo, Seung Bae Yoon · 2024 · Pancreatology
53. Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cells
    Mansour S. Alturki, Nada Tawfeeq, Amal Alissa, Zahra Ahbail, Mohamed Sayed Gomaa, Abdulaziz Hassan Al Khzem, Thankhoe A. Rants’o, Mohammad J. Akbar, Waleed S. Alharbi, Bayan Y. Alshehri et al. · 2025 · Informatics in Medicine Unlocked
54. Small Molecule Imaging Agent for Mutant KRAS G12C
    Peter David Koch, Jeremy M. Quintana, Maaz S. Ahmed, Rainer H. Köhler, Ralph Weissleder · 2021 · Advanced Therapeutics
55. Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
    Fanming Kong, Ziwei Wang, Dongying Liao, Jinhui Zuo, Hongxia Xie, Xiaojiang Li, Yingjie Jia · 2021 · Frontiers in Oncology
56. Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)
    Qifu Xu, Guozhen Zhang, Qian Liu, Shunda Li, Yingjie Zhang · 2022 · Expert Opinion on Therapeutic Patents
57. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome
    Alice Mogenet, Fabrice Barlési, Benjamin Besse, Stefan Michiels, Maryam Karimi, Alicia Tran-Dien, Nicolas Girard, Julien Mazières, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez et al. · 2022 · Lung Cancer
58. Colorectal cancer-derived exosomes and modulation KRAS signaling
    Yan Hua Wan, Qi Sheng Liu, Sha Sha Wan, Ri Wei Wang · 2022 · Clinical & Translational Oncology
59. Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells
    Karthikeyan Subbarayan, Chiara Massa, Sandra Leisz, André Steven, Daniel Bethmann, Katharina Biehl, Claudia Wickenhauser, Barbara Seliger · 2022 · OncoImmunology
60. Single‐cell transcriptomics dissects epithelial heterogeneity in HPV+ cervical adenocarcinoma
    Cong Wang, Lei Li, Fuhao Wang, Xia Li, Jujie Sun, Xiaohui Li, Tianyu Lei, Qingyu Huang, Guangyu Zhang, Hongqing Wang et al. · 2023 · Journal of Medical Virology
61. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma
    Robin Park, Mohammed Al‐Jumayli, Kirk A. Miller, Azhar Saeed, Anwaar Saeed · 2021 · Cancer Treatment and Research Communications
62. KRAS G12C inhibition and innate immune targeting
    Tetsuo Tani, Shunsuke Kitajima, Ella B. Conway, Erik H. Knelson, David Allen Barbie · 2021 · Expert Opinion on Therapeutic Targets
63. Technical aspects of the use of cytopathological specimens for diagnosis and predictive testing in malignant epithelial neoplasms of the lung
    Anthony John Maddox, Louise Smart · 2021 · Cytopathology
64. Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations
    Paul M. Yenerall, Rahul Krishna Kollipara, Kimberley Avila, Michael Peyton, Christopher A. Eide, Daniel Bottomly, Shannon K. McWeeney, Yan Liu, Kenneth D. Westover, Brian J. Druker et al. · 2021 · Cancer Research
65. Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing
    Xiaolan Hu, Jian‐Lin Wu, Quan He, Zhi‐Qi Xiong, Na Li · 2024 · Journal of Pharmaceutical Analysis
66. Clinical applications of circulating biomarkers in non-small cell lung cancer
    Hyun-Ji Oh, Abdulhamid B. Imam-Aliagan, Yeo-Bin Kim, Hyun Jin Kim, Issac A. Izaguirre, Chang K. Sung, Hyungshin Yim · 2024 · Frontiers in Cell and Developmental Biology
67. Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer
    Qinglian Hu, Jiayu Feng, Lulu Qi, Yuanxiang Jin · 2024 · ACS Applied Materials & Interfaces
68. Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
    Hannah Ruth Robinson, Stephanie Lakritz, Dean C. Pavlick, Sarah Lindsey Davis, Christopher Hanyoung Lieu, Corbin Jeffrey Eule, Laura S Graham, Philippe E. Spiess, R. Li, Ashish M. Kamat et al. · 2025 · ESMO Open
69. KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis
    Filip Marković, Jelena S. Milin-Lazovic, Nikola Nikolić, Aleksa Golubovic, Mihailo Stjepanović, Milica Kontić · 2025 · Current Oncology
70. Adagrasib in the treatment of colorectal cancer
    Sara F. Haddad, Youssef Bouferraa, Kanika G. Nair · 2025 · Future Oncology
71. Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D
    Balázs Budai, Andrea Vaupel, Callum J. Dickson, Kim S. Beyer, Daniel Alexander Guthy, Nils Ostermann, Lynn M. McGregor, Ruben de Kanter, Andreas Weiss, Markus Linder et al. · 2025 · Journal of Medicinal Chemistry
72. Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology
    Laura A. Levit, Mirat Shah, Mark J. Ratain, Elizabeth S. Garrett-Mayer, Atiqur Rahman, Marc Robert Theoret, Robert Donald Harvey · 2025 · Journal of Clinical Oncology
73. Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs
    Liam Baird, Lin Zhang, Takanori Hidaka, Lyu Xi, Ke Wang, Keiko Tateno, Tatsuro Iso, Takafumi Suzuki, Kazuki Kumada, Fumiki Katsuoka et al. · 2025 · British Journal of Cancer
74. Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
    Nicholas Endres, Steven Do, Rana M Mroue, Jack A. Terrett, Matt Saabye, Angela Oh, Thomas Hunsaker, Emily Chan, John C. Tran (1471192), Lan K. Nguyen et al. · 2026 · Journal of Medicinal Chemistry
75. Detection of actionable mutations in archived cytological bile specimens
    Hiroshi Ohyama, Yosuke Hirotsu, Kenji Amemiya, Toshio Oyama, Yuji Iimuro, Yuichiro Kojima, Rintaro Mikata, Hitoshi Mochizuki, Naoya Kato, Masao Omata · 2021 · Journal of Hepato-Biliary-Pancreatic Sciences
76. KRAS-targeted therapy in the treatment of non-small cell lung cancer
    Jina Yun, Reid Nakagawa, Kenneth W. Tham · 2022 · Journal of Oncology Pharmacy Practice
77. TargetingKRAS G12Cmutations in colorectal cancer
    Minghe Zhao, Aiwen Wu · 2022 · Gastroenterology report
78. Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases
    Dean G. Brown, Heike J. Wobst · 2023 · Bioorganic & Medicinal Chemistry
79. CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
    Shannon S. Zhang, Alexandria TM Lee, Misako Nagasaka · 2023 · Lung Cancer Targets and Therapy
80. CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
    Danielle Brazel, Jennifer Kim, Sai‐Hong Ignatius Ou · 2023 · Lung Cancer Targets and Therapy
81. Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients
    Feiwen Liu, Fang Wang, Jianbo He, Shaozhang Zhou, Min Luo · 2023 · Cancer Medicine
82. New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer
    Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters · 2023 · Current Treatment Options in Oncology
83. Clinicogenomic factors and treatment patterns among patients with advanced non–small cell lung cancer with or without brain metastases in the United States
    Emily Nash Smyth, Jincy John, Ramon Velasquez Tiu, Melinda D. Willard, Julie Kay Beyrer, Lee Bowman, Kristin M. Sheffield, Yimei Han, Priscilla Kaliopi Brastianos · 2023 · The Oncologist
84. Insights into how adeno-squamous transition drives KRAS inhibitor resistance
    Feng Hu, Piro Lito · 2024 · Cancer Cell
85. Perioperative and palliative systemic treatments for biliary tract cancer
    Hossein Taghizadeh, Yawen Dong, Thomas Gruenberger, Gerald W. Prager · 2024 · Therapeutic Advances in Medical Oncology
86. Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies
    Sravani Keerthi Ramisetty, Ayalur Raghu Subbalakshmi, Siddhika Pareek, Tamara Mirzapoiazova, Dana Do, Dhivya Prabhakar, Evan P. Pisick, Sagun Shrestha, Srisairam Achuthan, S. Bhattacharya et al. · 2024 · Journal of Clinical Medicine
87. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation
    Vida Tajiknia, Maximilian P. Pinho-Schwermann, Praveen R. Srinivasan, Liz J. Hernández Borrero, Leiqing Zhang, Kelsey E. Huntington, Wafik S. El‐Deiry · 2024 · American Journal of Cancer Research
88. Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
    Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben Lulu, Baisali Bhattacharya et al. · 2024 · Journal of Experimental & Clinical Cancer Research
89. KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
    Linyan Tian, Chengming Liu, Sufei Zheng, Huiyang Shi, Wei Fang, Wenxin Jiang, Yucheng Dong, Haiyan Xu, Enzhi Yin, Nan Sun et al. · 2025 · Journal of Translational Medicine
90. Effective design of therapeutic nanovaccines based on tumor neoantigens
    Weilin Wang, Yujia Zhai, Xiaoye Yang, Lei Ye, Guo‐Liang Lu, Xiaoqun Shi, Guangxi Zhai · 2025 · Journal of Controlled Release
91. Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer
    Gianluca Gragnano, Mariantonia Nacchio, Roberta Sgariglia, Floriana Conticelli, Antonino Iaccarino, Caterina De Luca, Giancarlo Troncone, Umberto Malapelle · 2021 · Journal of Clinical Pathology
92. K-RAS4A: Lead or Supporting Role in Cancer Biology?
    Veronica Aran · 2021 · Frontiers in Molecular Biosciences
93. Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects
    Jingwen Ma, Meng Li · 2021 · Translational Cancer Research
94. Development of a versatile HPLC-based method to evaluate the activation status of small GTPases
    Makoto Araki, Kaho Yoshimoto, Meguri Ohta, Toshiaki Katada, Kenji Kontani · 2021 · Journal of Biological Chemistry
95. Recent advances in lung cancer genomics: Application in targeted therapy
    Neha Pathak, Sindhura Durga Chitikela, Prabhat Singh Malik · 2021 · Advances in genetics
96. Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology
    Jessica A. Scarborough, Jacob G. Scott · 2021 · Seminars in Radiation Oncology
97. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
    Ritu Kulshrestha, Pawan Kumar, Amit Singh, K. Nupur, Sonam Spalgias, Parul Mrigpuri, Rajkumar · 2021 · Molecular Biomedicine
98. A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer
    Sara Mainardi, René Bernards · 2022 · Cell Genomics
99. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer
    Sofie Claerhout, Stefan Lehnert, Sara Vander Borght, Lien Spans, Christophe Dooms, Els Wauters, Johan Vansteenkiste, Birgit Weynand, Karen Deraedt, Claire Bourgain et al. · 2022 · Lung Cancer
100. Lung cancer: progress with prognosis and the changing state of play
     Fraser Brims, Annette M. McWilliams, Susan Harden, Kenneth John O'Byrne · 2022 · The Medical Journal of Australia